Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

AeRang Kim

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Communications Medicine|January 22, 2026
Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studiesWenjun Kang, Lorena Lazo de la Vega, Hannah Comeau, et al.
JAMA Oncology|January 30, 2016
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) StudyMarian H Harris, Steven G DuBois, Julia L Glade Bender, et al.
The New England Journal of Medicine|December 29, 2016
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasEva Dombi, Andrea Baldwin, Leigh J Marcus, et al.
Neuro-Oncology Practice|July 15, 2024
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseasesBritt A E Dhaenens, Günter Heimann, Annette Bakker, et al.
Neuro-Oncology|April 25, 2022
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidityAndrea M Gross, Brittany Glassberg, Pamela L Wolters, et al.
Pediatric Blood & Cancer|May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid TumorsFilemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
The Oncologist|June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm GMarie V Nelson, AeRang Kim, P Mickey Williams, et al.
American Journal of Medical Genetics. Part A|April 23, 2018
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisMichael J Fisher, Allan J Belzberg, Peter de Blank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
SARC031: A Phase 2 Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)AeRang Kim, Karla V Ballman, Pamela L Wolters, et al.
The New England Journal of Medicine|March 19, 2020
Selumetinib in Children with Inoperable Plexiform NeurofibromasAndrea M Gross, Pamela L Wolters, Eva Dombi, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Communications Medicine|January 22, 2026
Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studiesWenjun Kang, Lorena Lazo de la Vega, Hannah Comeau, et al.
JAMA Oncology|January 30, 2016
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) StudyMarian H Harris, Steven G DuBois, Julia L Glade Bender, et al.
The New England Journal of Medicine|December 29, 2016
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform NeurofibromasEva Dombi, Andrea Baldwin, Leigh J Marcus, et al.
Neuro-Oncology Practice|July 15, 2024
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseasesBritt A E Dhaenens, Günter Heimann, Annette Bakker, et al.
Neuro-Oncology|April 25, 2022
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidityAndrea M Gross, Brittany Glassberg, Pamela L Wolters, et al.
Pediatric Blood & Cancer|May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid TumorsFilemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
The Oncologist|June 14, 2024
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm GMarie V Nelson, AeRang Kim, P Mickey Williams, et al.
American Journal of Medical Genetics. Part A|April 23, 2018
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosisMichael J Fisher, Allan J Belzberg, Peter de Blank, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
SARC031: A Phase 2 Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)AeRang Kim, Karla V Ballman, Pamela L Wolters, et al.
The New England Journal of Medicine|March 19, 2020
Selumetinib in Children with Inoperable Plexiform NeurofibromasAndrea M Gross, Pamela L Wolters, Eva Dombi, et al.
Pageof 7